7-57 Wells Avenue
Newton, MA 11553
|Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.||Pres, CEO & Chairman||619,88k||N/A||1972|
|Ms. Jennifer J. Rhodes J.D.||Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec.||453,04k||N/A||1970|
|Mr. Gregory S. Curhan||Chief Financial Officer||N/A||N/A||1962|
|Mr. Daniel Iazzetti||VP of HR||N/A||N/A||N/A|
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
Angion Biomedica Corp.s ISS Governance QualityScore, Stand 30. März 2023, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 8, Shareholderrechte: 8, Kompensation: 9.